Tag: NSCLC
Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with...
Interim results from the phase IIb TARGET Trial, presented as Late-Breaking News at the annual meeting of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows improved survival in adenocarcinoma non-small cell lung cancer patients treated the small molecule drug conjugate (SMDC) vintafolide, being developed byEndocyte, in combination with docetaxel (Taxotere®; Sanofi).[1]
